Upgrades - Keefe Bruyette upgraded Bain Capital Specialty Finance (BCSF) to Outperform from Market Perform with an unchanged price target of $16, citing attractive entry point for shares [2] - JPMorgan upgraded Paccar (PCAR) to Overweight from Neutral with a price target of $133, increased from $108, due to offsetting tariff-related headwinds following the latest Section 232 proclamation [3] - Wells Fargo upgraded Generac (GNRC) to Overweight from Equal Weight with a price target of $195, up from $186, highlighting a "near-free call option" on data center growth after recent share pullback [4] - Barclays upgraded Cummins (CMI) to Overweight from Equal Weight with a price target of $546, increased from $515, reflecting new emissions rules and reduced R&D expenses [5] - Citizens upgraded Stryker (SYK) to Outperform from Market Perform with a price target of $440, citing reasonable valuation at current share levels [5] Downgrades - Wedbush downgraded Lyft (LYFT) to Underperform from Neutral with a price target of $16, down from $20, due to risks from autonomous vehicle disruption in the U.S. ridesharing market [6] - JPMorgan downgraded Lockheed Martin (LMT) to Neutral from Overweight with a price target of $515, up from $465, based on out-year cash flow estimates being below consensus [6] - Raymond James downgraded Allegiant Travel (ALGT) to Outperform from Strong Buy with a price target of $98, up from $78, citing valuation concerns after recent share strength [6] - Deutsche Bank downgraded Elevance Health (ELV) to Hold from Buy with a price target of $320, down from $332, due to reduced estimates and challenging macro environment [6] - Williams Trading downgraded Birkenstock (BIRK) to Hold from Buy with a price target of $51, down from $75, following earnings report and lack of clarity from management [6]

Core Viewpoint - Profound Medical Corp. announced a registered direct offering of 5,142,857 common shares at $7.00 per share, aiming for gross proceeds of up to $40 million, including a subsequent private placement of up to 571,428 shares at the same price [1][3][6] Group 1: Offering Details - The registered direct offering is structured as an equity investment with no warrant coverage, led by healthcare-dedicated investors [2] - Gross proceeds from the offering are expected to be approximately $36 million before deducting fees and expenses [3] - The private placement aims for up to $4 million in gross proceeds, with shares subject to a four-month hold period [6] Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for sales and marketing expansion, working capital, research and development, strategic transactions, and general corporate purposes [3] Group 3: Company Overview - Profound Medical Corp. is a commercial-stage medical device company focused on AI-powered, MRI-guided therapies for tissue ablation [7] - The company is commercializing TULSA-PRO, a technology for treating various prostate conditions, which is incision-free and has a quick recovery time [8] - Profound is also developing Sonalleve, a platform for treating uterine fibroids and other conditions, with approvals in multiple jurisdictions [9]

Core Viewpoint - Ocumetics Technology Corp. has amended the terms of its previously announced brokered private placement, aiming to raise up to $2.5 million through the issuance of units at an amended price of $0.60 per unit [1][2]. Group 1: Offering Details - The amended offering will consist of up to 4,166,666 units, each unit comprising one common share and one common share purchase warrant, with the warrant allowing the purchase of a share at $0.75 for three years [2]. - The Lead Agent has been granted an option to sell an additional 625,000 units at the same price, potentially raising an extra $375,000 [3]. - The offering is expected to close around December 29, 2025, subject to necessary approvals [7]. Group 2: Use of Proceeds - The gross proceeds from the offering are intended to fund the Corporation's first-in-human clinical trials, ongoing research and development, and general corporate purposes [4]. Group 3: Regulatory and Compliance - The units will be offered through a private placement under specific exemptions in Canada and the United States, with no prospectus filing required in certain jurisdictions [5]. - Participation by insiders in the offering will be considered a related party transaction but is expected to be exempt from formal valuation and minority shareholder approval requirements [8]. Group 4: Company Overview - Ocumetics Technology Corp. is focused on developing advanced vision correction solutions, including innovative intraocular lenses designed to eliminate the need for corrective lenses [10][11].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [4][5]. Stock Price Decline - On October 23, 2025, Integer revised its 2025 sales guidance down to a range of $1.840 billion to $1.854 billion from a previous range of $1.850 billion to $1.876 billion, which was below analysts' expectations. The company also projected poor net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026. This announcement led to a stock price drop of $35.22 per share, or over 32%, from $109.11 to $73.89 [6].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Minnesota, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Inspire stock [3]. - Investors have until January 5, 2026, to request to lead the case [3]. Group 2: Company Background - Inspire Medical Systems develops and manufactures an implantable medical device for treating sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Group 3: Allegations and Stock Impact - Inspire allegedly misled investors by claiming it had taken necessary steps for the launch of Inspire V, while in reality, it failed to prepare clinicians and payors, leading to delays and weak demand [5][6]. - On August 4, 2025, Inspire announced an "elongated timeframe" for the Inspire V launch and reduced its 2025 earnings per share guidance by over 80%, causing the stock price to drop by $42.04, or more than 32%, from $129.95 to $87.91 per share [7][8].

国家药监局召开脑机接口医疗器械工作推进会。会议要求，要坚持安全有效为首要前提，构建标准体系，加强技术指导服务；要加强跨部门合作，联手产学研医各方，合力解决关键技术问题，完善产业链供应链；要落实企业主体责任，提升产品可靠性和整体竞争力，积极推动脑机接口器械更快更好服务临床。 ...

As filed with the U.S. Securities and Exchange Commission on December 18, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Envoy Medical, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 3842 86-1369123 (IRS Employer Identification Number) 4875 White Bear ...

As filed with the U.S. Securities and Exchange Commission on December 18, 2025. Registration No. 333- (State or other jurisdiction of incorporation or organization) FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Envoy Medical, Inc. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Primary Standard Industrial Classification Code Number) Delaware 3842 86-1369123 (IRS Employer Identification Number) 4875 White Bear ...

Core Viewpoint - A class action securities lawsuit has been filed against Integer Holdings Corporation, alleging securities fraud that adversely affected investors between July 25, 2024, and October 22, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Integer Holdings materially overstated its competitive position in the electrophysiology manufacturing market [2]. - It is alleged that despite claims of strong visibility into customer demand, the company was experiencing a sustained decline in sales related to two of its electrophysiology devices [2]. - The complaint further asserts that Integer mischaracterized its electrophysiology devices as a long-term growth driver for its cardio & vascular segment [2]. - As a result of these issues, the positive statements made by the defendants regarding the company's business and prospects were deemed materially false and misleading [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until February 9, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - A class action securities lawsuit has been filed against Inspire Medical Systems, Inc. due to alleged securities fraud affecting investors between August 6, 2024, and August 4, 2025 [1]. Group 1: Lawsuit Details - The lawsuit claims that the launch of Inspire Medical Systems' new product, Inspire V, was unsuccessful due to poor demand and excess inventory at treatment centers, contradicting prior assurances from the company [2]. - Allegations include that Inspire Medical Systems failed to complete essential tasks for the product launch, such as training for treatment center customers, setting up IT systems, and ensuring proper Medicare reimbursement [2]. Group 2: Next Steps for Investors - Investors who experienced losses during the specified timeframe have until January 5, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be eligible for compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4].